Ifm Investors Pty LTD Bei Gene, Ltd. Transaction History

Ifm Investors Pty LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 13, 2022	BUY	$146.52 - $269.56 $253,333 - $466,069	1,729 New	1,729 $326,000
Q4 2020 Jan 13, 2021	SELL	$221.31 - $316.61 $736,962 - $1.05 Million	-3,330 Closed	0 $0
Q3 2020 Oct 16, 2020	BUY	$189.18 - $286.44 $67,348 - $101,972	356 Added 11.97%	3,330 $954,000
Q2 2020 Jul 13, 2020	SELL	$123.9 - $195.41 $3,593 - $5,666	-29 Reduced 0.97%	2,974 $560,000
Q1 2020 Apr 09, 2020	BUY	$121.84 - $173.19 $42,156 - $59,923	346 Added 13.02%	3,003 $377,000
Q4 2019 Jan 13, 2020	SELL	$115.78 - $208.34 $31,144 - $56,043	-269 Reduced 9.19%	2,657 $440,000
Q3 2019 Nov 01, 2019	BUY	$120.61 - $148.29 $117,835 - $144,879	977 Added 50.13%	2,926 $358,000
Q2 2019 Jul 16, 2019	BUY	$113.99 - $146.86 $14,362 - $18,504	126 Added 6.91%	1,949 $242,000
Q4 2018 Jan 23, 2019	BUY	$107.01 - $175.15 $195,079 - $319,298	1,823 New	1,823 $256,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Ifm Investors Pty LTD, based on Form 13F filings with the SEC.

Stay updated on Ifm Investors Pty LTD with notifications on news.